[The use of transdermal fentanyl in chronic non-malignant pain].
Twelve non-malignant pain patients were followed-up for pain, improvement in the quality of life, satisfaction for pain therapy and side effects for a mean of 95.25 days with the use of transdermal fentanyl (TDF). During this period a mean of 32.04 mg/gr TDF was used. While the score of pain at rest was decreased by 52.6%, mean pain score on movement was decreased by 45.2% (p= 0.002). Quality of sleep improved and impairment of daily living by pain was decreased significantly (p= 0.002). Satisfaction by the pain therapy was 83.3% and the most common side effect was nausea (16.8%). TDF may be a good alternative in the therapy of chronic non-malignant pain if patients were selected carefully.
Akkaya
Taylan
T
SSK Ankara Training Hospital, Department of Anesthesiology and Intensive Care, Ankara, Turkey. taylanakkaya@hotmail.com
Sayin
Murat
M
Gümüş
Haluk
H
D000203:Activities of Daily Living; D000279:Administration, Cutaneous; D000701:Analgesics, Opioid / Q000008:administration & dosage*; D002908:Chronic Disease; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy*; D010147:Pain Measurement; D012890:Sleep; D016896:Treatment Outcome
D000701:Analgesics, Opioid; D005283:Fentanyl